Josselson alias Dr. Neurotransmitter Nonsense

Josselson is not licensed or approved by No governing board to diagnose, treat, or cure Thyroid Support.

Thyroid Support

Supports

High-quality evidence specifically supporting a broad claim of generic thyroid support is limited. One randomized-trial meta-analysis found that long-term exercise-based interventions can improve some thyroid-function measures in people with hypothyroidism, suggesting exercise may be a useful adjunct in selected patients . A 2025 systematic review and meta-analysis reported that a gluten-free diet may improve some outcomes in non-celiac Hashimoto’s thyroiditis, but this is a narrow subgroup finding rather than evidence for thyroid support in general .

Contradicts

The claim is too vague to be directly supported as stated, and there is no major guideline or broad systematic review in the list endorsing unspecified thyroid support for the general population. The exercise meta-analysis applies only to hypothyroidism and addresses function, not an all-purpose thyroid-support intervention . The gluten-free diet meta-analysis applies only to non-celiac Hashimoto’s thyroiditis and does not establish benefit for people without that condition or for thyroid health broadly . The remaining listed papers are unrelated to thyroid support and do not provide evidentiary backing for the claim.

Mainstream view

Mainstream endocrinology does not recognize a generic thyroid support intervention as an evidence-based medical category. Evidence-based care focuses on diagnosing and treating specific thyroid disorders, correcting identified deficiencies when present, and using standard therapies such as levothyroxine for hypothyroidism or condition-specific management for other thyroid diseases. Lifestyle measures may be adjunctive in selected patients, but broad thyroid-support claims are not supported as a general medical recommendation.

Papers listed for this claim:[1][2][3][4][5][6][7][8]

In their own wordsView sourceArchived copy

“Thyroid Support”

See every doc bro who says they can treat or advise on Thyroid disease and Hashimoto

Josselson is not licensed or approved by No governing board to diagnose, treat, or cure Depression.

Depression

Supports

A 2011 narrative review argued that neurotransmitters excreted in urine may have a place in clinical practice as biomarkers of nervous system function and to assess disturbances and monitor treatment efficacy, suggesting some potential for urinary neurotransmitter measurements as biomarkers of nervous system activity rather than direct diagnostic tests. A 2023 worker-screening study reported that urinary neurotransmitters could be a promising indicator to determine underlying mental stress, with levels reported to decrease in individuals with depression; the authors explicitly framed them as potential biomarkers for monitoring mental health conditions and assessing degree of mental stress, not as standalone diagnostic tools. Historical monoamine research and CSF studies show modest correlations between central monoamine metabolites and certain symptom dimensions (e.g., anxiety/agitation in depression), indicating that neurochemical measures can have some association with mood and anxiety symptoms, but these are research correlations with limited clinical diagnostic utility. Peripheral blood monoamine metabolite levels have been explored as predictors of depressive severity and treatment response, again suggesting some biomarker potential rather than formal diagnostic capability.

Contradicts

A detailed critique of "spot baseline" urinary monoamine assays concluded that there are no defined applications where such assays can be used to diagnose disease or other states directly, and that no peer‑reviewed original research demonstrates these assays are valid for treatment of individual patients in clinical settings; the marketing model claiming urinary monoamines as biomarkers for ADHD and depression was judged not clinically proven and without scientific foundation. Major guideline methodology papers emphasize that high‑quality evidence and validated clinical outcomes are required before adopting diagnostic tools; neurotransmitter testing is not mentioned as a diagnostic modality for psychiatric conditions in major guidelines, indicating lack of endorsement and evidentiary support. Historical monoamine hypothesis reviews note that urinary monoamine metabolites (e.g., MHPG) are poor indicators of CNS neurotransmitter turnover, heavily influenced by peripheral sources and factors like physical activity, undermining the premise that peripheral or urinary levels can reliably represent brain neurotransmitter status for diagnostic purposes. Contemporary expert commentaries and clinical resources state that urinary neurotransmitter testing does not accurately reflect CNS neurotransmitter levels, should not be used to diagnose psychiatric or neurological conditions, and is not supported by major medical authorities for guiding psychotropic treatment or diagnosing depression, anxiety, ADHD, or other behavioral disorders. The available clinical research on urinary neurotransmitters and mental stress frames these measures as potential screening or monitoring biomarkers with acknowledged limitations, explicitly noting that urinary levels may not reflect brain levels, which directly contradicts using them as definitive diagnostic tests for depression, anxiety, insomnia, fatigue, or ADHD. Overall, there are no randomized trials, large prospective diagnostic accuracy studies, or major psychiatric guidelines validating neurotransmitter testing as a diagnostic tool for the conditions claimed; existing supportive materials are largely methodological, marketing, or exploratory and do not meet the threshold for diagnostic validation.

Mainstream view

Mainstream psychiatry and neurology diagnose depression, anxiety disorders, insomnia, fatigue-related syndromes, and ADHD based on standardized clinical criteria, structured interviews, and validated symptom scales, often complemented by targeted laboratory tests to rule out medical causes, but they do not rely on neurotransmitter testing (urine, saliva, or peripheral blood levels of monoamines) as a diagnostic tool for these conditions. The dominant scientific view is that while neurotransmitters are central to the pathophysiology of mood and behavioral disorders, peripheral or urinary measurements are influenced by multiple systemic and metabolic factors and do not provide a reliable proxy for CNS neurotransmitter function at the individual level. Major guidelines for psychiatric and neurological disorders focus on clinical assessment and, where applicable, neuropsychological testing or imaging, and do not include commercial neurotransmitter panels as recommended diagnostic tests for depression, anxiety, insomnia, fatigue, or ADHD, reflecting a consensus that such testing lacks sufficient validity and evidence for routine diagnostic use. Neurotransmitter or monoamine metabolite measures may be used in research settings and are being explored as potential biomarkers for stress or treatment response, but current evidence supports only limited, investigational roles rather than formal diagnosis of specific psychiatric conditions.

Papers listed for this claim:[1][3][4][6][8][9][10][11][12][13][14][15]

In their own wordsView sourceArchived copy

“Depression”

See every doc bro who says they can treat or advise on Depression

Josselson is not licensed or approved by No governing board to diagnose, treat, or cure Behavioral problems (including ADD/ADHD).

Behavioral problems (including ADD/ADHD)

Supports

A 2011 narrative review argued that neurotransmitters excreted in urine may have a place in clinical practice as biomarkers of nervous system function and to assess disturbances and monitor treatment efficacy, suggesting some potential for urinary neurotransmitter measurements as biomarkers of nervous system activity rather than direct diagnostic tests. A 2023 worker-screening study reported that urinary neurotransmitters could be a promising indicator to determine underlying mental stress, with levels reported to decrease in individuals with depression; the authors explicitly framed them as potential biomarkers for monitoring mental health conditions and assessing degree of mental stress, not as standalone diagnostic tools. Historical monoamine research and CSF studies show modest correlations between central monoamine metabolites and certain symptom dimensions (e.g., anxiety/agitation in depression), indicating that neurochemical measures can have some association with mood and anxiety symptoms, but these are research correlations with limited clinical diagnostic utility. Peripheral blood monoamine metabolite levels have been explored as predictors of depressive severity and treatment response, again suggesting some biomarker potential rather than formal diagnostic capability.

Contradicts

A detailed critique of "spot baseline" urinary monoamine assays concluded that there are no defined applications where such assays can be used to diagnose disease or other states directly, and that no peer‑reviewed original research demonstrates these assays are valid for treatment of individual patients in clinical settings; the marketing model claiming urinary monoamines as biomarkers for ADHD and depression was judged not clinically proven and without scientific foundation. Major guideline methodology papers emphasize that high‑quality evidence and validated clinical outcomes are required before adopting diagnostic tools; neurotransmitter testing is not mentioned as a diagnostic modality for psychiatric conditions in major guidelines, indicating lack of endorsement and evidentiary support. Historical monoamine hypothesis reviews note that urinary monoamine metabolites (e.g., MHPG) are poor indicators of CNS neurotransmitter turnover, heavily influenced by peripheral sources and factors like physical activity, undermining the premise that peripheral or urinary levels can reliably represent brain neurotransmitter status for diagnostic purposes. Contemporary expert commentaries and clinical resources state that urinary neurotransmitter testing does not accurately reflect CNS neurotransmitter levels, should not be used to diagnose psychiatric or neurological conditions, and is not supported by major medical authorities for guiding psychotropic treatment or diagnosing depression, anxiety, ADHD, or other behavioral disorders. The available clinical research on urinary neurotransmitters and mental stress frames these measures as potential screening or monitoring biomarkers with acknowledged limitations, explicitly noting that urinary levels may not reflect brain levels, which directly contradicts using them as definitive diagnostic tests for depression, anxiety, insomnia, fatigue, or ADHD. Overall, there are no randomized trials, large prospective diagnostic accuracy studies, or major psychiatric guidelines validating neurotransmitter testing as a diagnostic tool for the conditions claimed; existing supportive materials are largely methodological, marketing, or exploratory and do not meet the threshold for diagnostic validation.

Mainstream view

Mainstream psychiatry and neurology diagnose depression, anxiety disorders, insomnia, fatigue-related syndromes, and ADHD based on standardized clinical criteria, structured interviews, and validated symptom scales, often complemented by targeted laboratory tests to rule out medical causes, but they do not rely on neurotransmitter testing (urine, saliva, or peripheral blood levels of monoamines) as a diagnostic tool for these conditions. The dominant scientific view is that while neurotransmitters are central to the pathophysiology of mood and behavioral disorders, peripheral or urinary measurements are influenced by multiple systemic and metabolic factors and do not provide a reliable proxy for CNS neurotransmitter function at the individual level. Major guidelines for psychiatric and neurological disorders focus on clinical assessment and, where applicable, neuropsychological testing or imaging, and do not include commercial neurotransmitter panels as recommended diagnostic tests for depression, anxiety, insomnia, fatigue, or ADHD, reflecting a consensus that such testing lacks sufficient validity and evidence for routine diagnostic use. Neurotransmitter or monoamine metabolite measures may be used in research settings and are being explored as potential biomarkers for stress or treatment response, but current evidence supports only limited, investigational roles rather than formal diagnosis of specific psychiatric conditions.

Papers listed for this claim:[1][3][4][6][8][9][10][11][12][13][14][15]

In their own wordsView sourceArchived copy

“Behavioral problems (including ADD/ADHD)”

See every doc bro who says they can treat or advise on ADHD

Josselson is not licensed or approved by No governing board to diagnose, treat, or cure PMS and hormonal imbalance.

PMS and hormonal imbalance

Supports

There is moderate supportive evidence that some complementary and lifestyle interventions used by naturopathic or integrative practitioners can reduce PMS symptom severity, but this support is for specific modalities rather than for generic “naturopathic doctor treatment.” High-quality randomized controlled trials show benefit of non-pharmacologic interventions such as aerobic exercise, diet modification, yoga, progressive muscle relaxation, auriculotherapy, aromatherapy with specific essential oils, and psychological interventions for PMS symptom clusters, including mood and pain. Several RCTs and systematic reviews indicate that certain herbs and nutritional supplements (e.g., calcium, vitamin B6, chasteberry/Vitex agnus castus, chamomile, selected Iranian herbal preparations, and multi‑nutrient formulations) can improve PMS symptoms, particularly when used in standardized doses under clinical trial conditions. More recent meta-analyses conclude that herbal medicine and nutritional supplements may be effective and generally safe for PMS when studied in controlled settings, though effects and quality of evidence vary by product and study.

Contradicts

There is no high-quality evidence demonstrating that the broad construct of “naturopathic doctor treatment of PMS and hormonal imbalance” as a holistic package is superior to standard medical care or to specific evidence-based interventions, and most trials focus on single modalities rather than comprehensive naturopathic protocols. Evidence for many popular naturopathic interventions is weak, inconsistent, or based on small, heterogeneous studies that limit firm conclusions; systematic reviews emphasize that no complementary or alternative therapy can be unequivocally recommended as a stand‑alone treatment for PMS on current evidence because of methodological limitations, publication bias, and heterogeneity of the syndrome. Several widely promoted herbal products and supplements (such as evening primrose oil and some forms of magnesium) show no clear benefit over placebo, and the quality of evidence for many other botanicals or homeopathic remedies remains low. There is also limited or no rigorous evidence that naturopathic approaches can reliably “correct hormonal imbalance” as a disease entity in PMS, beyond modest modulation of symptoms and possible indirect effects via weight loss, stress reduction, or improved lifestyle. Guidelines and mainstream reviews focus on specific agents (e.g., SSRIs, hormonal contraceptives, calcium, vitamin B6, certain botanicals) and lifestyle measures rather than endorsing naturopathy as a distinct therapeutic system.

Mainstream view

The mainstream medical position is that premenstrual syndrome is best managed with a combination of evidence‑based pharmacologic and non‑pharmacologic interventions tailored to symptom severity, not by a specific professional label such as “naturopathic doctor.” First‑line or widely accepted options include selective serotonin reuptake inhibitors for moderate to severe PMS or premenstrual dysphoric disorder, combined hormonal contraceptives, and targeted lifestyle strategies such as regular aerobic exercise, sleep optimization, stress management, and dietary adjustments. Some nutrients (notably calcium and possibly vitamin B6) and selected herbal products (particularly standardized Vitex agnus castus preparations and chamomile) are recognized as having supportive trial data, but they are generally considered adjuncts rather than replacements for established therapies, and clinicians are advised to discuss product quality, dosing, safety, and potential interactions. Major reviews in gynecology and women’s health consider complementary and integrative therapies on an intervention‑by‑intervention basis and do not endorse naturopathy as a unified, guideline‑driven treatment model for PMS or for vaguely defined “hormonal imbalance.” Overall, mainstream practice supports using specific complementary measures that have demonstrated benefit within a shared decision‑making framework, while maintaining skepticism about broad claims that naturopathic treatment as a whole can reliably and comprehensively treat PMS or normalize hormones without robust, system‑level evidence.

Papers listed for this claim:[1][3][4][6][9][8][10][11][16][17][18][19]

In their own wordsView sourceArchived copy

“PMS and hormonal imbalance”

See every doc bro who says they can treat or advise on Hormone imbalance and replacement